Anorexia Nervosa and Its Effects on Brain Function, Body Metabolism and Their Interaction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-01

Study Completion Date

2024-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The neuromolecular and metabolic underpinnings of Anorexia Nervosa (AN) are studied using multi-modal molecular (positron emission tomography with two different radioligands) and functional (functional magnetic resonance imaging) neuroimaging in a prospective design. Subjects with AN and normal weight adolescents will be studied with PET and MRI and followed for five years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of sixty females (30 with AN, 30 healthy controls) are recruited into this prospective study. The subjects will undergo physical examination, body tissue composition measurement, functional and structural MRI of the brain and body, and positron emission tomography (PET) with ligands \[18F\]-FDG, and \[11C\]carfentanil. Subjects' weight and physical condition will be followed up for 5 years. The study will start in August 2020 and end in the fall of 2028.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anorexia Nervosa

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Anorexia nervosa metabolism functional imaging PET

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients and controls

AN patients and controls are recruited, studied using imaging and followed for 5 years

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Female sex
2. Age 18-32 3 years
3. BMI \< 17.5 kg/m2
4. Currently fulfilling modified DSM-IV diagnosis of AN with or without amenorrhea, onset age before 25 years
5. Diagnosed less than 2 years ago

For controls:

1. Female sex
2. Age 18-32 3 years
3. BMI 19 20-25 kg/m2
4. No lifetime history of obesity (BMI ≥\> 30) or eating disorders

Exclusion Criteria

1. Any chronic disease or medication that could affect glucose metabolism or neurotransmission
2. History of psychiatric disorders (excl. AN for the corresponding study group)
3. Smoking of tobacco, taking of snuffs, or use of narcotics
4. Abusive use of alcohol

Minimum Eligible Age

18 Years

Maximum Eligible Age

32 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pirjo Nuutila

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pirjo Nuutila, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Turku PET Centre, Turku University hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Turku PET Centre

Turku, , Finland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Finland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

T113/2020

Identifier Type: -

Identifier Source: org_study_id